Alle Studien
RekrutierungPHASE3INTERVENTIONELL

A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis

This research is investigating a new medicine, elafibranor, for adults diagnosed with Primary Sclerosing Cholangitis (PSC). PSC is a rare liver condition that causes inflammation and scarring in the bile ducts, which can lead to serious liver problems over time. The study aims to find out if elafibranor is effective and safe in treating PSC, compared to a placebo (a tablet with no active medicine). About 350 people will take part, receiving either the active medicine or the placebo once a day. Researchers will regularly check participants' liver health, symptoms, and general well-being. The study will run for several years, with a follow-up period after treatment finishes, to see how the medicine impacts the disease in the long term.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE3
Sponsor
Ipsen
Einschreibeziel
350
Starten
14. Mai 2026
Geschätzte Fertigstellung
31 May 2031

Worum geht es in dieser Studie?

This study is designed to learn more about a potential new medicine called elafibranor for a serious liver condition called Primary Sclerosing Cholangitis, or PSC. PSC is a rare disease where the small tubes in your liver, called bile ducts, become inflamed and scarred. These ducts are important because they carry bile, a fluid that helps digest food, from your liver to your gut. Over time, this scarring can damage the liver and lead to serious health issues, sometimes requiring a liver transplant. There's currently no cure, so finding new treatments is really important.

The main goal of this study is to see if elafibranor can help slow down or stop the damage to the bile ducts and improve the health of people with PSC. We also want to make sure the medicine is safe and doesn't cause too many side effects. To do this, we'll be comparing elafibranor to a 'placebo' – that's a dummy pill that looks exactly like the medicine but contains no active ingredients. This helps us understand if any changes seen are truly due to the medicine or something else.

About 350 adults with PSC will take part in this research. They will be randomly chosen to receive either elafibranor or the placebo. Participants will be carefully monitored throughout the study, with regular check-ups, blood tests, and scans. This will help doctors understand how their liver is doing, if their symptoms are improving, and how the medicine might be affecting their overall health and quality of life. The study is expected to last for several years, allowing us to see the long-term effects of the treatment.

Wichtige Erkenntnisse

  • This study is testing a new medicine called elafibranor for Primary Sclerosing Cholangitis (PSC).
  • It aims to see if the medicine is safe and helps reduce liver inflammation and scarring.
  • Participants will receive either elafibranor or a dummy pill (placebo) and be monitored closely.
  • The study could last for several years, with regular check-ups, blood tests, and scans.
  • Sie können jederzeit aus der Studie austreten, ohne dass dies Ihre medizinische Versorgung beeinträchtigt.

Wer könnte berechtigt sein?

To be able to join this study, you would need to be an adult aged 18 or older with a confirmed diagnosis of Primary Sclerosing Cholangitis (PSC). Your liver disease should be 'compensated,' meaning your liver is still working reasonably well, and you must be able to follow the study's instructions and attend appointments. If you are a woman who could become pregnant, you would need to use highly effective contraception throughout the study.

There are also some reasons why you might not be able to join. For example, if you have other serious liver diseases, have had a liver transplant, or have complications from advanced liver scarring (cirrhosis). You also wouldn't be able to take part if you've had recent surgery on your bile ducts or a recent bile duct infection. Certain serious medical conditions, a history of some cancers, or taking particular medications that could interfere with the study medicine would also mean you can't participate. The study team will review all your medical information carefully to see if you are a good fit.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Are you an adult aged 18 or over?
  2. Do you have a confirmed diagnosis of Primary Sclerosing Cholangitis (PSC)?
  3. Is your liver disease currently 'compensated' (still functioning reasonably well)?
  4. Are you able to follow study instructions and attend regular appointments?
  5. If you are a woman who could become pregnant, are you willing to use highly effective birth control throughout the study?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, you'll first have a screening period to check if you're suitable for the study. Once accepted, you'll be randomly assigned to take either the study medicine (elafibranor) or a dummy pill (placebo) once a day. You won't know which one you're taking, and neither will your study doctor.

Throughout the study, you'll have regular visits to the clinic for check-ups. These will involve routine physical exams, blood tests, and scans to monitor your liver and general health. You'll also be asked to fill out questionnaires to tell us about your symptoms and how you're feeling. The treatment period is expected to be quite long, possibly several years, until enough health events occur among all participants to give clear results, likely around 5 years. After you finish taking the study medicine, there will be a final safety check-up about four weeks later. You are free to withdraw from the study at any time, for any reason.

Potenzielle Risiken und Vorteile

Taking part in any clinical study has potential benefits and potential risks. You might benefit from the new medicine if it proves to be effective in treating PSC, which could slow the progression of your liver disease. However, as with any medicine, elafibranor could cause side effects, some of which might be unpleasant or serious. Since some participants will receive a placebo, they won't get any active treatment from the study drug, but will still have regular monitoring. The study team will monitor you closely for any health changes or side effects. Remember, you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Standorte (231)

  • Arizona Liver Health
    Verifizierte Postleitzahl
    Chandler, Vereinigte Staaten· Rekrutierung
  • Mayo Clinic in Arizona
    Verifizierte Postleitzahl
    Phoenix, Vereinigte Staaten· Noch nicht rekrutiert
  • Southern California Research Center
    Verifizierte Postleitzahl
    Coronado, United States· Rekrutierung
  • Universität von Kalifornien San Diego
    Verifizierte Postleitzahl
    La Jolla, Vereinigte Staaten· Noch nicht rekrutiert
  • Keck Medicine of USC - USC Healthcare Center 1
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten· Noch nicht rekrutiert
  • Cedars-Sinai Medical Center
    Verifizierte Postleitzahl
    Los Angeles, Vereinigte Staaten· Noch nicht rekrutiert
  • California Liver Research Institute
    Verifizierte Postleitzahl
    Pasadena, Vereinigte Staaten· Rekrutierung
  • Stanford University
    Verifizierte Postleitzahl
    Redwood City, Vereinigte Staaten· Noch nicht rekrutiert
  • Universitätsklinikum der University of California, Davis
    Verifizierte Postleitzahl
    Sacramento, Vereinigte Staaten· Noch nicht rekrutiert
  • Sutter Health Van Ness Campus Medical Office Building
    Verifizierte Postleitzahl
    San Francisco, Vereinigte Staaten· Noch nicht rekrutiert
  • University of California, San Francisco Medical Center
    Verifizierte Postleitzahl
    San Francisco, Vereinigte Staaten· Rekrutierung
  • University of Colorado Hospital Anschutz Outpatient Pavilion
    Verifizierte Postleitzahl
    Aurora, Vereinigte Staaten· Noch nicht rekrutiert

Häufige Fragen

What is Primary Sclerosing Cholangitis (PSC)?

PSC is a rare liver disease where the bile ducts inside your liver become inflamed and scarred, which can lead to liver damage over time.

Was ist ein 'Placebo'?

A placebo is a dummy pill that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers understand if the real medicine is having an effect.

Wie lange werde ich an der Studie teilnehmen?

The treatment part of the study is expected to last for several years, possibly around 5 years, with a short follow-up period afterwards.

Kann ich die Teilnahme an der Studie beenden, wenn ich meine Meinung ändere?

Yes, you are completely free to leave the study at any time, for any reason, without it affecting your regular medical care.

Will I know if I'm taking the real medicine or the dummy pill?

No, this is a 'blinded' study, meaning neither you nor your study doctor will know whether you are receiving elafibranor or the placebo.

Wie Sie mehr erfahren können

Ipsen Clinical Study Enquiries

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Study to Assess How Well and Safely Elafibranor Works in A… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.